Table 2. Univariable and multivariable analysis of risk factors for the time of ir-hepatitis occurrence.
| Characteristics | Univariable analysis | Multivariable analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Sex (male vs. female) | 0.587 (0.250–1.375) | 0.220 | 0.591 (0.155–2.254) | 0.441 | |
| Age (>65 vs. ≤65 years) | 0.986 (0.499–1.947) | 0.968 | 1.631 (0.655–4.061) | 0.294 | |
| Smoking history (ever vs. never) | 1.306 (0.647–2.634) | 0.456 | 0.710 (0.201–2.512) | 0.595 | |
| Drinking history (ever vs. never) | 1.291 (0.639–2.609) | 0.477 | 0.901 (0.332–2.442) | 0.837 | |
| Histology (adenocarcinoma vs. squamous carcinoma) | 1.295 (0.656–2.555) | 0.457 | 2.218 (0.779–6.314) | 0.136 | |
| PS (0 vs. 1) | 0.612 (0.181–2.065) | 0.429 | 0.503 (0.114–2.211) | 0.363 | |
| Hepatitis virus infection (yes vs. no) | 0.705 (0.265–1.876) | 0.483 | 0.265 (0.062–1.129) | 0.073 | |
| Liver metastases (yes vs. no) | 1.078 (0.325–3.571) | 0.903 | 1.222 (0.270–5.537) | 0.795 | |
| Line of immunotherapy (1 vs. ≥2) | 0.598 (0.290–1.234) | 0.164 | 0.419 (0.140–1.255) | 0.120 | |
| Treatment pattern (monotherapy vs. combination therapy) | 0.777 (0.348–1.737) | 0.539 | 1.211 (0.337–4.349) | 0.769 | |
Ir-hepatitis, immune-related hepatitis; HR, hazard ratio; CI, confidence interval; PS, performance status.